Attovia Therapeutics doses first participant in phase 1 study of ATTO-1310, its novel HLF anti-IL-31 ATTOBODY to treat chronic pruritus: Fremont, California Saturday, January 25, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback